LDS/Medical Tests/Human Immunodeficiency Virus (HIV) 1 and 2 Western Blot Confirmation Assay

Human Immunodeficiency Virus (HIV) 1 and 2 Western Blot Confirmation Assay

Human Immunodeficiency Virus (HIV), sometimes called human T-lymphotrophic virus Type II (HTLV-III), has two genotypes – Type 1 and Type 2. The Type 1 virus is common throughout the United States and Europe, while Type 2 is mainly found in West Africa. High-risk populations include intravenous drug users, sexually active male homosexuals, people with multiple sexual partners, and newborns exposed to HIV in utero or during delivery. Individuals receiving contaminated blood product transfusions are also at risk, but current screening procedures have greatly reduced this mode of infection.

Although the parenteral transmission mode of HIV infection remains important, the most common mode of transmission is sexual. Viremia occurs in 4 to 11 days with RNA levels often in excess of 1,000,000 copies per mL. Seroconversion usually occurs within 2 to 6 weeks after exposure to infection, although it may occur earlier or much later in some cases.

The new CDC guidelines recommend screening for HIV using 4th generation HIV-1/2 Ag/Ab combo immunoassay (preferred) or 3rd generation HIV-1/2 immunoassay (acceptable) followed by the supplemental testing by HIV-1/HIV-2 antibody differentiation immunoassay or Western blot immunoassay which will differentiate between HIV1 and HIV2. Most recent versions of Western blot immunoassay can differentiate between HIV1 and HIV2.

  • Confirmation and differentiation of individual antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV-1 and HIV-2)
  • Confirm the presence of antibodies to HIV-1 and HIV-2 for specimens found to be repeatedly reactive by diagnostic screening procedures
  • If the supplemental test is positive for HIV1 or HIV2 or both, the interpretation is “Positive for HIV-1 and/or 2 antibody” and no further testing is required and medical care is recommended
  • Additional testing for HIV-1 RNA and HIV-2 RNA or DNA is recommended at the initial clinical evaluation to verify or rule-out HIV-1/HIV-2 dual infection if supplemental testing was positive for both
  • If the result of the Western blot HIV-1/HIV-2 antibody differentiation test is “Nonreactive” or “Indeterminate,” testing of the specimen should reflex to an HIV-1 RNA assay to rule out false positive immunoassay results
  • If the initial HIV-1/2 immunoassay was reactive and HIV-1 RNA is detected, the final interpretation is “Positive for HIV-1” and medical care should be initiated
  • If HIV-1 RNA is not detected, the final interpretation is “Negative for HIV-1.” The initial HIV-1/2 immunoassay result was most likely a false positive

Negative (Non-Reactive)
 

 

 

Western blot antibody detection (immunoblotting).

Serum (SST), plasma (EDTA). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
HIV RNA by RT-PCR (Viral load), HIV Genotyping, HIV Phenotyping.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • MMWR Morb Mortal Wkly Rep. 2013 Jun 21;62(24):489-94. [PMID: 23784012]
  • Clin Med. 2003 May-Jun;3(3):203-5. [PMID: 12848250]
  • Infect Dis Clin North Am. 2000 Dec;14(4):791-808. [PMID: 11144639]
  • J Clin Microbiol. 1998 Aug;36(8):2235-9. [PMID: 9665998]
  • MLO Med Lab Obs. 2004;36:12. [PMID: 15318787]
  • Contraception. 2004 Aug;70(2):141-7. [PMID: 15288219]
  • Murray PR et al. (editors): Manual of Clinical Microbiology, 8th ed. ASM Press (2003).
  • Pagana D & Pagana T. (2010). Mosby’s Manual of Diagnostic and Laboratory Tests (4th ed.). St. Louis, MO: Mosby.